Navigation Links
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Date:4/18/2011

and has been instrumental in its growth during his six and a half years at the Company," said Mr. Crowley. "He has a strong track record of success throughout his 18-year career in the field of rare disease drug development, having overseen the advancement of novel therapies through development into commercialization. I am confident Matt has the experience and capabilities to lead Amicus during this important time in the Company's history."

Mr. Patterson joined Amicus in December 2004 as Chief Business Officer and became Chief Operating Officer in September 2006. He was recently appointed President in February 2011 in recognition of his significant contributions to the Company's success. Prior to Amicus, Mr. Patterson served in positions of increasing responsibility at biopharmaceutical companies focused on rare disease drug research, development, and commercialization, including BioMarin Pharmaceutical Inc. and Genzyme Corporation.

Mr. Crowley will serve as Executive Chairman and a member of the Board of Directors until October 2011, with a possible extension for up to three months upon the mutual agreement of Mr. Crowley and the Company.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program is in Phase 3 for the treatment of Fabry disease. 

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
2. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
3. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
4. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
5. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
6. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
7. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
8. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
9. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
10. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
11. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 A victim of medical ... doctor with a history of alcohol abuse, a ... Yes on Prop 46 today, highlighting how Prop 46 will ... alcohol testing. The ad pictures a doctor ... "911-Report To ER."  Proposition 46 will enact the first law ...
(Date:10/17/2014)... , Oct. 17, 2014 The following ... Technology Policy: The Green Park Collaborative ... public and private payers, medical device and pharmaceutical ... other experts January 12, 2015 at its first ... of weight loss treatments.  Participants will discuss study ...
(Date:10/17/2014)... Conn. , Oct. 17, 2014  UBM Medica ... online community for endocrinologists and other clinicians who treat ... comprehensive coverage on effective use of insulin .  ... eventually require insulin replacement therapy – daily ... for the progressive decline in the function of pancreatic ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... 2011 What:   Investigators ... of FDA,s 510(k) regulatory pathway—through which more than 90% ... it. The study is the most comprehensive survey to ... Center for Devices and Radiological Health (CDRH) is currently ...
... SOUTH SAN FRANCISCO, Calif., May 18, 2011 Onyx ... the presentation of several studies evaluating carfilzomib, a selective, ... inhibitor, in hematological cancers at the 47th American Society ... in Chicago, IL. "The data that will ...
Cached Medicine Technology:Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 2Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 3Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 4Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 5Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 6Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 7
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... 12 HOUR for use in treating symptoms of seasonal allergic ... a combination of desloratadine 2.5 mg and pseudoephedrine sulfate, USP ... in persons above 12 years of age. The drug ... non-nasal symptoms occurring due to seasonal allergic rhinitis. Two ...
... India’s National Institute of Immunology are reported to have ... how the tuberculosis (TB) bacteria survives in the human ... and more effective medicines to combat the disease, which ... world annually. The research team led by Rajesh S. ...
... new survey has found that many British workers are not averse ... be sent in by text messages or the typical cough and ... is the widespread dissatisfaction with holiday allowance for British workers, who ... ,'Early February is a very popular time for ...
... leaders, particularly in South Asia to prohibit smoking among the ... the British Medical Journal (BMJ). The help of the Muslim ... ,The researchers analyzed data on the prevalence of smoking ... Smoking rates in each of these countries is significantly higher ...
... topic for several years, gaining momentum over the past one ... physiological responses to them. A new study, published in the ... effect of types of placebo devices Vs pills on patients ... placebos to gauge the effectiveness of novel treatment methods, but ...
... of Health said that conventional tests fail to identify smaller blood ... sign because they do not have the bulky clogs in main ... shortness of breath and are at an increased risk of a ... is very common among both men and women and causes maximum ...
Cached Medicine News:Health News:Placing a Finger on Responses to Placebo Types 2
... surface preparation is the Leica SM2500 sledge ... ,Ultramilling is often a viable alternative to ... preparation. Especially with difficult specimens, where hard ... side in one specimen block, the results ...
... The Trellis Infusion Catheter enables the physician ... physician-specified fluid, and disperse the agent by ... The Trellis is a multi-lumen catheter with ... end and infusion holes located between these ...
... The SENSAR® Acrylic IOL with OptiEdge ... performance, long-term refractive stability, and excellent handling. ... has had no reports of vacuoles; the ... internal reflections and provide 360 degrees of ...
... acrylic foldable single-piece posterior chamber lenses are ... human crystalline lens in the visual correction ... age and older. The optical portion consists ... material. These lenses have biconvex optics and ...
Medicine Products: